Objective: To compare the outcomes and evaluate the relative risk of thyroid cancer by using the UK thyroid fine-needle aspiration (FNA) cytological diagnostic categories, with the main objective being the clarity of patient management. Study Design: Results of thyroid FNA reported as Thy3a, Thy3f, Thy4, and Thy5 were correlated with histological outcomes. The specificity and positive predictive value (PPV; risk of malignancy) for each reporting category was assessed. Results: Of a total of 873 thyroid FNAs, 237 (27%) were reported as ‘abnormal’: 40 (4.6%) as Thy3a, 119 (13.6%) as Thy3f, 20 (2.2%) as Thy4, and 58 (6.6%) as Thy 5. The final outcomes were available in 136 (57%) cases which underwent surgical resection (25, 60, 55, and 74% of Thy3a, Thy3f, Thy4, and Thy5, respectively). The known outcomes of the Thy3a category were too low to be statistically significant. The specificity and PPV of the Thy3f, Thy4, and Thy5 (equivalent to the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) IV, V, and VI) categories were 50, 50, and 100% and 28, 64, and 100%, respectively. The PPV of Thy3f for diagnosis of ‘neoplasms’ (benign and malignant) was 63%. Conclusion: The current thyroid FNA classification system used in the UK, which is comparable to TBSRTC, offers a sound basis for clear communication on which the management of patients with abnormal thyroid FNA findings can be based. Categories Thy3f, Thy4, and Thy5 carry a progressively rising risk of malignancy, justifying their continuing use. Diagnostic category Thy5 ‘malignant’ is robust and can be used as a sure indication of a definitive surgical management.

1.
Gray W, Kocjan G (eds): Diagnostic Cytopathology, ed 3. New York, Elsevier Science, 2010.
2.
National Institute for Health and Clinical Excellence: Improving outcomes in head and neck cancers. 2004. http://www.nice.org.uk/guidance/csghn/guidance/pdf/English.
3.
Kocjan G, Cochand-Priollet B, de Agustin PP, et al: Diagnostic terminology for reporting thyroid fine needle aspiration cytology: European Federation of Cytology Societies thyroid working party symposium, Lisbon 2009. Cytopathology 2010;21:86–89.
4.
British Thyroid Association, Royal College of Pathologists: Guidelines for reporting of thyroid cytology specimens. 2009. http://www.rcpath.org/resources/pdf/g089guidanceonthereportingofthyroidcytologyfinal.pdf.
5.
Royal College of Pathologists: Dataset for thyroid cancer histopathology reports. 2006. http://www.rcpath.org/resources/pdf/ThyroidDatasetFeb06.pdf (accessed May 24, 2009).
6.
Royal College of Pathologists: Tissue pathways for endocrine pathology. 2008. http://www.rcpath.org/resources/pdf/g078_tpendocrine_jul08.pdf.
7.
Cooper DS, Doherty GM, Haugen BR, Kloss RT, et al: Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109–142.
8.
Gharib H: Fine-needle aspiration biopsy of thyroid nodules: advantages, limitations, and effect. Mayo Clin Proc 1994;69:44–49.
9.
British Association of Otorhinolaryngologists – Head and Neck Surgeons: Effective Head and Neck Cancer Management: Third Consensus Document. London, Royal College of Surgeons, 2002.
10.
Department of Health: Manual for cancer services: head and neck special measures. 2006. http://www.dh.gov.uk/en/Healthcare/NationalServiceFrameworks/Cancer/DH_4135595.
11.
Kocjan G, Chandra A, Cross P, Denton K, Giles T, Herbert A, Smith P, Remedios D, Wilson P: BSCC Code of Practice – fine needle aspiration cytology. Cytopathology 2009;20:283–296.
12.
Layfield L, Cibas ES, Gharib H, Mandel S: Thyroid aspiration cytology: current status. CA Cancer J Clin 2009;59:99–110.
13.
Zagorianakou P, Malamou-Mitsi V, et al: The role of FNA in the management of patients with thyroid nodules. In Vivo 2005;19:605–609.
14.
Kocjan G, Chandra A, Cross PA, et al: The interobserver reproducibility of thyroid fine-needle aspiration using the UK Royal College of Pathologists’ classification system. Am J Clin Pathol 2011;135:852–859.
15.
Abati A: The National Cancer Institute Thyroid FNA State of the Science Conference: ‘wrapped up’. Diagn Cytopathol 2008;36:388–389.
16.
Cibas ES, Alexander EK, Benson CB, et al: Indications for thyroid FNA and pre-FNA requirements: a synopsis of the National Cancer Institute Thyroid FNA State of the Science Conference. Diagn Cytopathol 2008;36:390–399.
17.
Baloch ZW, LiVolsi VA, Asa SL, et al: Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008;36:425–437.
18.
Layfield LJ, Abrams J, Cochand-Priollet B, at al: Post-thyroid FNA testing and treatment options: a synopsis of the National Cancer Institute Thyroid FNA State of the Science Conference. Diagn Cytopathol 2008;36:442–448.
19.
Pitman MB, Abele J, Ali SZ, et al: Techniques for thyroid FNA: a synopsis of the National Cancer Institute Thyroid FNA State of the Science Conference. Diagn Cytopathol 2008;36:407–424.
20.
Baloch ZW, Cibas ES, Clark DP, Layfield LJ, Ljung BM, Pitman MB, Abati A: The National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference: a summation. Cytojournal 2008;5:6.
21.
Redman R, Yoder BJ, Massoll NA: Perceptions of diagnostic terminology and cytopathologic reporting of fine-needle aspiration biopsies of thyroid nodules: a survey of clinicians and pathologists. Thyroid 2006;10:1003–1008.
22.
Mazzaferri EL: Management of a solitary thyroid nodule. N Engl J Med 1993;328:553–559.
23.
Theoharis CG, Schofield KM, et al: The Bethesda Thyroid Fine Needle Aspiration Classification System: year 1 at an academic institution. Thyroid 2009;19:1215–1223.
24.
Amrikachi M, Ramzy I, et al: Accuracy of FNA of thyroid. Arch Pathol Lab Med 2001;125:484–488.
25.
Yang J, Schnadig V, et al: FNA of thyroid nodules: a study of 4,703 patients with histologic and clinical correlations. Cancer 2007;11:306–315.
26.
Guidelines of the Papanicolaou Society of Cytopathology for fine needle aspiration procedure and reporting – the Papanicolaou Society of Cytopathology Taskforce on Standards of Practice. Diagn Cytopathol 1997;17:239–247.
27.
Baloch ZW, LiVolsi VA: FNA of thyroid nodules: past, present and future. Endoc Pract 2004;10:234–241.
28.
Eedes CR, Wang HH: Cost-effectiveness of immediate specimen adequacy assessment of thyroid FNA. Am J Clin Pathol 2004;121:64–69.
29.
Kelly NP, Lim JC, DeJong S, et al: Specimen adequacy and diagnosticspecificity of thyroid nodules. Diagn Cytopathol 2006;34:188–190.
30.
Poller DN, Stelow EB, Yiangou C: Thyroid FNAC cytology: can we do it better? Cytopathology 2008;19:4–10.
31.
Ali S, Cibas ES: The Bethesda System for Reporting Thyroid Cytopathology. New York, Springer, 2010.
32.
Mehrotra P, Viswanathan H, Johnson SJ, Wadehra V, Richardson DL, Lennard TWJ: Ultrasound guidance improves the adequacy of our pre-operative thyroid cytology but not its accuracy. Cytopathology 2006;17:137–144.
33.
Bomeisl PE Jr, Alam S, Wakely PE Jr: Interinstitutional consultation in fine-needle aspiration cytopathology: a study of 742 cases. Cancer 2009;117:237–246.
34.
Belfiore A, La Rosa GL: Fine-needle aspiration biopsy of the thyroid. Endocrinol Metab Clin North Am 2001;30:361–400.
35.
Haberal AN, Toru S, Ozen O, Arat Z, Bilezikci: Diagnostic pitfalls in the evaluation of fine needle aspiration cytology of the thyroid: correlation with histopathology in 260 cases. Cytopathology 2009;20:103–108.
36.
Lakhani R, Rourke T, Jefferis A, Perry L, Ghiacy S, Wood S: Thy3 cytology: what to do next? Ann R Coll Surg Engl 2011;93:225–228.
37.
Faquin WC, Baloch ZW: Fine-needle aspiration of follicular patterned lesions of the thyroid: diagnosis, management and follow-up according to National Cancer Institute recommendations. Diagn Cytopathol 2010;38: 731–739.
38.
Nayar R, Ivanovic M: The indeterminate Thyroid Fine–Needle Aspiration. Cancer Cytopathology 2009;117:195–2002.
39.
Layfield LJ, Morton MJ, Cramer HM: Implications of the proposed thyroid fine-needle aspiration category of ‘follicular lesion of indeterminate significance’: a five-year multi-institutional analysis. Diagn Cytopathol 2009;37:710–714.
40.
Agarwal A, Kocjan G: FNA thyroid reporting categories: value of using the British Thyroid Association (Thy1 to Thy5) thyroid FNA reporting guidelines. Cytopathology 2009;20:133–134.
41.
Roh MH, Jo VY, Stelow EB, Faquin WC, Zou KH, Alexander EK, Larsen PR, Marqusee E, Benson CB, Frates MC, Gawande A, Moore FD Jr, Cibas ES: The predictive value of the fine-needle aspiration diagnosis ‘suspicious for a follicular neoplasm, Hürthle cell type’ in patients with Hashimoto thyroiditis. Am J Clin Pathol 2011;135:139–145.
42.
Yassa L, Cibas ES, Benson CB, Frates MC, Doubilet PM, Gawande AA, Moore FD, Kim BW, Nosé V, Marqusee E, Reed Larsen P, Alexander EK: Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer 2007;111:508–516.
43.
Goldfarb M, Perry Z, A Hodin R, Parangi S: Medical, surgical risks in thyroid surgery: lessons from the NSQIP. Ann Surg Oncol 2011, E-pub ahead of print.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.